Extremely exciting research into a “new” antibody targeting CLL cells. Note that it may be of particular interest both because of its promising Phase 1 trial results AND because of its long half life.
Also, it is being developed by Dr. Kipps and team at the Moore Cancer Center at UCSD and NOT Big Pharma. This may bode well for access for those with no or inadequate insurance or in countries with government-run universal healthcare programs.
ASH 2012 Interview: Dr Jeff Sharman \"Why New CLL Treatments Supersede FCR\"
Other illnesses associated with CLL?
ibrutinib it is expensive?
Surprise delivery of priority PCR kit this morning
